Therapeutic cancer vaccines: The latest advancement in targeted therapy

American Journal of Therapeutics

Volumn 19, Issue 6, 2012, Pages

  Bilusic, Marijo ^a   Madan, Ravi A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

anti CTLA 4; combination therapy; immunotherapy; Therapeutic cancer vaccines

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EMEPEPIMUT S; ETOPOSIDE; IPILIMUMAB; LYMPHOMA VACCINE; MELANOMA ANTIGEN A3 VACCINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CYTOKINE PRODUCTION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INJECTION SITE REACTION; LONG TERM SURVIVAL; LUNG NON SMALL CELL CANCER; LYMPHOCYTE PROLIFERATION; MULTICENTER STUDY (TOPIC); NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; THERAPY; UNSPECIFIED SIDE EFFECT;

ANIMALS; CANCER VACCINES; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84870242257     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182068cdb     Document Type: Review

References (64)

1. FDA approves a cellular immunotherapy for men with advanced prostate cancer. Available at: http://www.fda. gov/NewsEvents/Newsroom/ PressAnnouncements/ucm 210174.htm
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252. (Pubitemid 28155090)
3. Tanaka K, Tanahashi N, Tsurumi C, et al. Proteasomes and antigen processing. Adv Immunol. 1997;64:1-38. (Pubitemid 27161386)
4. Hammer GE, Kanaseki T, Shastri N. The final touches make perfect the peptide-MHC class I repertoire. Immunity. 2007;26:397-406. (Pubitemid 46603005)
5. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11:3353-3362. (Pubitemid 40627887)
6. Parmiani G, Russo V, Marrari A, et al. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res. 2007;13:5675-5679. (Pubitemid 47583892)
7. Ribas A, Butterfield LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415-2432. (Pubitemid 46621880)
8. Jemal A, Siegel R,Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
9. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001-1011.
10. Fishman M. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer. Expert Opin Biol Ther. 2009;9:1565-1575.
11. Becker JT, Olson BM, Johnson LE, et al. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits longterm T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33:639-647.
12. Epel M, Carmi I, Soueid-Baumgarten S, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol. 2008;38:1706-1720.
13. Cereda V, Poole DJ, Palena C, et al. New gene expressed in prostate: a potential target for Tcell-mediated prostate cancer immunotherapy. Cancer Immunol Immunother. 2010;59:63-71.
14. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther. 2006;6:1163-1167. (Pubitemid 44575570)
15. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate. 2004;60:197-204. (Pubitemid 38971831)
16. Beinart G, Rini BI, Weinberg V, et al. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005;4:55-60. (Pubitemid 41018184)
17. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18:3894-3903.
18. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-422.
19. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099-1105.
20. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther. 2004;4:575-588. (Pubitemid 38480556)
21. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007;178:1515-1520. (Pubitemid 47368382)
22. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663-674.
23. Lechleider RJ, Arlen PM, Tsang KY, et al. Safety and immunologic response of a viral vaccine to prostatespecific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res. 2008;14:5284-5291.
24. Powell E, Chow LQ. BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer. Expert Rev Respir Med. 2008;2:37-45. (Pubitemid 352015320)
25. Huang L, Ren J, Chen D, et al. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2003;2:702-706.
26. Apostolopoulos V, McKenzie IF. Cellular mucins: targets for immunotherapy. Crit Rev Immunol. 1994;14:293-309.
27. Vlad AM, Kettel JC, Alajez NM, et al. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol. 2004;82:249-293. (Pubitemid 38209513)
28. Butts C,Murray N,Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall-cell lung cancer. J Clin Oncol. 2005;23:6674-6681. (Pubitemid 46190262)
29. Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01 [abstract]. J Thorac Oncol. 2007;2:S332-S333.
30. Gulley JL, Madan RA, Arlen PM. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine. 2007;25(Suppl 2):B89-B96. (Pubitemid 47488548)
31. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957-4971.
32. Zhang XM, Zhang YF, Huang Y, et al. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides. Oncol Rep. 2008;20:245-252.
33. Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25:131-134. (Pubitemid 38019071)
34. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179:921-930. (Pubitemid 24065650)
35. Gridelli C, Rossi A, Maione P, et al. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist. 2009;14:909-920.
36. Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer. 2009;10:371-374.
37. Federico M, Molica S, Bellei M, et al. Prognostic factors in low-grade non-Hodgkin lymphomas. Curr Hematol Malig Rep. 2009;4:202-210.
38. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood. 1997;89:3129-3135.
39. Schuster S, Neelapu S, Gause B, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results [abstract]. J Clin Oncol. 2009;27(18 suppl):2.
40. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol. 2003;13:135-147. (Pubitemid 36321814)
41. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ Tcell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167:1137-1140. (Pubitemid 32703105)
42. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276. (Pubitemid 34441324)
43. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455-458.
44. Mule JJ, Schwarz SL, Roberts AB, et al. Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother. 1988;26:95-100. (Pubitemid 18098858)
45. Farsaci B, Sabzevari H, Higgins J, et al. Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer. 2010;127: 1603-1613.
46. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270:985-988.
47. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-618. (Pubitemid 34752469)
48. Allison JP, Chambers C, Hurwitz A, et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp. 1998;215:92-98; discussion 98-102, 186-190.
49. Hodge JW, Chakraborty M, Kudo-Saito C, et al. Multiple costimulatory modalities enhance CTL avidity. J Immunol. 2005;174:5994-6004. (Pubitemid 40663786)
50. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
51. GerritsenW, Van Den Eertwegh A, De Gruijl T, et al. A doseescalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC) [abstract]. J Clin Oncol. 2006; 24(18 suppl):2500.
52. Gerritsen W, Van Den Eertwegh A, De Gruijl T, et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract]. J Clin Oncol. 2008;26(Suppl):5146.
53. Madan R, Mohebtash M, Arlen P, et al. Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2010;28(15 suppl):2550.
54. Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86:1712-1719. (Pubitemid 29513039)
55. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24:4721-4730. (Pubitemid 46630936)
56. Madan RA, Gulley JL, Fojo T, et al. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist. 2010;15:969-975.
57. Czerkinsky C, Andersson G, Ekre HP, et al. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon- secreting cells. J Immunol Methods. 1988;110:29-36.
58. Ryan JE, Ovsyannikova IG, Dhiman N, et al. Interoperator variation in ELISPOT analysis of measles virusspecific IFN-gamma-secreting T cells. Scand J Clin Lab Invest. 2005;65:681-689. (Pubitemid 41759164)
59. Cox JH, Ferrari G, Kalams SA, et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68-81. (Pubitemid 40179803)
60. Almeida CA, Roberts SG, Laird R, et al. Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses. J Immunol Methods. 2009;344:1-5.
61. Hernandez-Fuentes MP, Warrens AN, Lechler RI. Immunologic monitoring. Immunol Rev. 2003;196:247-264. (Pubitemid 37468115)
62. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother. 2008;57:1381-1390.
63. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115:3670-3679.
64. Stewart F, de la Rosa C, Sheikh N, et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer [abstract]. J Clin Oncol. 2010;28(15 suppl):4552.